The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship between serum HER2 level and histologic HER2 status in patients with advanced/recurrent gastric cancer.
Takahide Sasaki
Research Funding - Siemens Healthcare Diagnostics
Nozomu Fuse
Research Funding - Siemens Healthcare Diagnostics
Takeshi Kuwata
No relevant relationships to disclose
Mari Takahashi
No relevant relationships to disclose
Hiromichi Asano
Employment or Leadership Position - Siemens Healthcare Diagnostics
Research Funding - Siemens Healthcare Diagnostics
Kazuhiro Kaneko
No relevant relationships to disclose
Toshihiko Doi
No relevant relationships to disclose
Takayuki Yoshino
No relevant relationships to disclose
Takashi Kojima
No relevant relationships to disclose
Atsushi Ochiai
No relevant relationships to disclose
Atsushi Ohtsu
No relevant relationships to disclose